ABRACL

Across TCGA pan-cancer cohorts, ABRACL mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ABRACL’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where ABRACL mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ABRACL is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

COAD, LSCC, and HNSC are the cancer types where ABRACL tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ABRACL mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	All	+0.761	<.001	9	view →
LSCC	All	All	+0.810	<.001	8	view →
HNSC	Male	IV	+0.708	<.001	8	view →
PDAC	All	All	+0.522	<.001	5	view →
CCRCC	Male	All	−0.249	<.001	5	view →
LUAD	All	All	+0.218	.003	3	view →
OV	All	All	+2.117	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ABRACL–COAD

Open the COAD breakdown →